Candida
This resource provides information on Candida infections, including Candidiasis and Thrush, for healthcare professionals. Learn about diagnosis, clinical documentation, and medical coding for yeast infections. Find details relevant to Candida albicans and other Candida species to support accurate and efficient healthcare coding and documentation practices.
Fungal infection caused by Candida species, most commonly Candida albicans.
White patches, itching, redness, and burning sensation. Can affect skin, mouth, genitals, and other areas.
Skin folds, mouth (oral thrush), vagina (vaginal yeast infection), diaper area, and nails.
ICD-10 Code Families
Complete code families applicable to B37.9
When to use each related code
| Description | When to use |
|---|---|
| Fungal infection caused by Candida species. | Use for infections of skin, mouth, genitals, or systemic candidiasis. Consider species if known. |
| Invasive fungal infection, often affecting immunocompromised. | Use for serious, disseminated candidiasis involving deep tissues or organs. Specify species if known. |
| Superficial fungal infection of the mouth, commonly seen in infants. | Use specifically for oral candidiasis in newborns or infants. Often presents as white patches. |
Best-practice checklist
- ✓Document species (e.g., C. albicans)
- ✓Site of infection (e.g., oral, vaginal)
- ✓Clinical manifestations (e.g., white plaques, itching)
- ✓Diagnostic methods (e.g., KOH prep, culture)
- ✓Risk factors (e.g., antibiotic use, diabetes)
Common pitfalls to avoid
Coding Candida without specifying the affected site (e.g., oral, skin) leads to coding errors and claim denials. Proper documentation is crucial for accurate Candida coding.
Lack of clinical indicators validating Candida diagnosis can cause inaccurate coding and compliance issues. CDI specialists should query physicians for supporting documentation.
Coding Candida based on symptoms alone without confirmatory lab tests risks inaccurate diagnosis coding and impacts reimbursement. Ensure proper testing and documentation.
Best-practice tips
- 01Control blood sugar for Candida prevention. ICD-10 B37
- 02Proper hygiene reduces infection risk. SNOMED CT 82272006
- 03Avoid excessive antibiotic use. RxNorm 746742
- 04Boost immunity with probiotics and healthy diet. LOINC 2283-8
- 05Antifungal meds as prescribed. ICD-10 B37.9
Step-by-step checklist
- 1
Confirm patient symptoms (white patches, itching, burning)
- 2
Check affected area (mouth, skin, genitals, etc.)
- 3
Review patient history (diabetes, antibiotics, immunosuppression)
- 4
Consider KOH prep or culture for definitive diagnosis
- 5
Document species (if available) for targeted treatment
Ready-to-paste narrative
Patient presents with symptoms suggestive of Candida infection (Candidiasis, Thrush, Yeast Infection). Clinical findings include [Specify location of infection, e.g., oral thrush, vaginal yeast infection, cutaneous candidiasis, invasive candidiasis] characterized by [Describe specific signs and symptoms, e.g., white plaques on tongue, buccal mucosa, or vaginal walls; itching, burning, redness, swelling; thick, white discharge; skin rash with satellite lesions]. Differential diagnosis includes [List relevant differential diagnoses, e.g., bacterial vaginosis, streptococcal pharyngitis, contact dermatitis, intertrigo]. Diagnostic workup may include [Specify diagnostic tests performed or planned, e.g., KOH prep, fungal culture, Gram stain, blood cultures]. Based on the patient's presentation and [state the basis for diagnosis, e.g., positive KOH showing pseudohyphae and budding yeast, clinical findings], a diagnosis of [Specify type of Candida infection, e.g., oral candidiasis, vulvovaginal candidiasis, intertriginous candidiasis, candidemia] is made. Treatment plan includes [Detail prescribed medications, dosage, route, and frequency, e.g., Fluconazole 150mg PO single dose for vaginal yeast infection, Nystatin oral suspension for oral thrush, topical antifungal creams for cutaneous candidiasis]. Patient education provided regarding [Mention patient education topics, e.g., medication administration, hygiene practices, risk factors for recurrence, follow-up care]. Follow-up scheduled in [Specify timeframe, e.g., 1-2 weeks] to assess treatment response and address any ongoing symptoms. ICD-10 code [Specify appropriate ICD-10 code, e.g., B37.89 for other specified systemic candidiasis] is documented for billing and coding purposes. This documentation supports medical necessity for the prescribed treatment.
Common questions and answers
What are the most effective diagnostic strategies for differentiating between various types of Candida infections in clinical practice?+
Differentiating between various Candida species, such as Candida albicans, Candida glabrata, and Candida auris, requires a multifaceted approach. Culture-based methods remain the gold standard, allowing for species identification and antifungal susceptibility testing. CHROMagar Candida, a differential culture medium, can aid in presumptive identification based on colony color. Molecular methods, like PCR, offer rapid and sensitive detection, especially valuable for identifying Candida auris. Non-culture methods, such as mannan and anti-mannan antibody detection, can be useful for diagnosing invasive candidiasis. Histopathology, examining tissue samples for fungal elements, provides definitive diagnosis in tissue-invasive disease. Choosing the appropriate diagnostic strategy depends on the suspected infection site (e.g., bloodstream, mucosal surfaces, deep-seated organs) and the patient's clinical presentation. Explore how combining these methods can improve diagnostic accuracy and inform targeted antifungal therapy. Consider implementing rapid diagnostic tests in high-risk patient populations to facilitate prompt treatment.
How can clinicians effectively manage recurrent vulvovaginal candidiasis (RVVC) in patients who fail to respond to standard antifungal treatments?+
Recurrent vulvovaginal candidiasis (RVVC), defined as four or more episodes per year, presents a significant challenge for both clinicians and patients. Managing RVVC requires a comprehensive approach that addresses potential predisposing factors, such as uncontrolled diabetes, antibiotic use, and hormonal influences. Confirming the diagnosis with culture is crucial to rule out non-albicans Candida species, which may exhibit reduced susceptibility to azoles. For patients failing standard short-course azole therapy, long-term maintenance therapy with oral fluconazole or topical azoles for 6-12 months may be necessary. Non-pharmacological strategies, including avoiding tight-fitting clothing, maintaining optimal vulvovaginal hygiene, and managing underlying medical conditions, are also essential. Explore the role of probiotic supplementation and its potential benefits in restoring vaginal microbiota balance. Learn more about antifungal resistance testing and its utility in guiding treatment decisions in refractory cases.
What are the key clinical considerations and recommended antifungal treatment strategies for managing candidemia in critically ill patients?+
Candidemia in critically ill patients carries a high mortality rate, necessitating prompt and appropriate antifungal therapy. Early initiation of empiric antifungal therapy, ideally within 24 hours of suspicion, is crucial. Echinocandins are generally recommended as first-line therapy due to their broad-spectrum activity and favorable safety profile. Fluconazole can be considered in patients with low risk of fluconazole resistance and no recent azole exposure. Source control, which involves removing central venous catheters and draining infected collections, is paramount for successful treatment. The duration of antifungal therapy should be individualized based on clinical response, microbiological clearance, and resolution of signs and symptoms. Consider implementing strategies to minimize the risk of antifungal resistance, such as appropriate antifungal stewardship programs. Learn more about the role of combination antifungal therapy in specific patient populations, such as those with persistent fungemia or infections caused by resistant Candida species.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.